Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose-response assessment strategies for endocrine-active compounds

H A Barton1, M E Andersen

  • 1ICF Kaiser, Research Triangle Park, North Carolina 27709, USA.

Regulatory Toxicology and Pharmacology : RTP
|June 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic drivers: A systematic review and meta-analysis.

Critical reviews in oncology/hematology·2026
Same author

Using available <i>in vitro</i> metabolite identification and time course kinetics for β-chloroprene and its metabolite, (1-chloroethenyl) oxirane, to include reactive oxidative metabolites and glutathione depletion in a PBPK model for β-chloroprene.

Frontiers in pharmacology·2023
Same author

Response to "letter concerning: Clewell (2019) incorporation of <i>in vitro</i> metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene." (UIHT-2020-0053).

Inhalation toxicology·2020
Same author

Derivation of whole blood biomonitoring equivalents for titanium for the interpretation of biomonitoring data.

Regulatory toxicology and pharmacology : RTP·2020
Same author

Toxicity testing in the 21st century: progress in the past decade and future perspectives.

Archives of toxicology·2019
Same author

Assessing children's exposure to manganese in drinking water using a PBPK model.

Toxicology and applied pharmacology·2019

Biologically based dose-response assessments offer a promising approach for evaluating endocrine-active compounds (EACs). These methods improve upon traditional models by considering mode-of-action and pharmacokinetics for better risk assessment.

Area of Science:

  • Toxicology and Environmental Health
  • Endocrinology and Pharmacology

Background:

  • Current risk assessment for endocrine-active compounds (EACs) heavily relies on hazard identification.
  • Traditional dose-response assessments use empirical models that limit extrapolation of animal study results to humans, especially at low doses.
  • Existing methods struggle with the complexities of EACs affecting normal physiological endocrine signaling.

Purpose of the Study:

  • To explore the potential of biologically based dose-response (BBDR) assessments for endocrine-active compounds (EACs).
  • To propose a shift from empirical analysis to mechanistic understanding for EAC risk assessment.
  • To address the challenge of quantifying EAC risks by focusing on interactions with fundamental biological control mechanisms.

Main Methods:

Related Experiment Videos

  • Utilizing knowledge of mode-of-action (pharmacodynamics) and dosimetry (pharmacokinetics) for BBDR assessments.
  • Focusing on normal physiological endocrine signaling pathways and their regulatory mechanisms.
  • Investigating how exogenous compounds interact with signaling components like receptors and second messengers.

    • Main Results:

    • BBDR assessments offer a more robust framework for quantitative dose-response evaluations of EACs.
    • These biologically informed approaches can better handle low-dose and interspecies extrapolation challenges.
    • Understanding interactions with homeostatic control mechanisms is key to predicting EAC dose-response behaviors.

    Conclusions:

    • Biologically based dose-response assessments are crucial for advancing the regulatory strategies of endocrine-active compounds.
    • Integrating pharmacodynamics and pharmacokinetics provides a more comprehensive understanding of EAC effects.
    • Future risk assessment should prioritize mechanistic insights into how EACs disrupt endocrine signaling pathways.